US Edition
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention
Summary by Simply Wall St
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Teva (TEVA) Is Up 5.7% After FDA Approves AJOVY for Pediatric Migraine Prevention
Teva Pharmaceutical Industries recently received U.S. FDA approval for AJOVY as the first and only CGRP antagonist for preventive treatment of episodic migraine in children and adolescents aged 6-17 weighing at least 45 kilograms, expanding its reach within pediatric neurology. This approval, combined with improved second quarter earnings and a raised revenue outlook, marks important momentum in Teva's efforts to diversify and strengthen its neu…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
